Javascript doit fonctionner ! Activez-le et rechargez cette page.
Le Rézo de JeuxDeMots
• Types de relations
• Types de noeuds
• Consolider
le terme
  Options  
             

  Filtrage type relations : +   - (ex: 4, 12, 18, 36, 444, 555, 777)
  Filtrage valeur :          min   max
  Filtrage type noeuds :   +   - (ex: 4, 6, 8, 9, 10, 12, 18, 36, 444, 555, 777)

  Présentation de sortie :   (ex: -rien-, cloud, nicecloud)
 

'en:hla-b*5801 assay negative'
(id=6809381 ; fe=en:hla-b*5801 assay negative ; type=1 ; niveau=200 ; luminosité=25 ; somme entrante=2448 creation date=2017-06-25 touchdate=2025-08-27 17:21:09.000)
≈ 78 relations sortantes

  1. en:hla-b*5801 assay negative -- r_associated #0: 43 / 1 -> en:cd49d expression
    n1=en:hla-b*5801 assay negative | n2=en:cd49d expression | rel=r_associated | relid=0 | w=43
  2. en:hla-b*5801 assay negative -- r_associated #0: 42 / 0.977 -> en:il-2 receptor assay
    n1=en:hla-b*5801 assay negative | n2=en:il-2 receptor assay | rel=r_associated | relid=0 | w=42
  3. en:hla-b*5801 assay negative -- r_associated #0: 41 / 0.953 -> en:galectin-3 abnormal
    n1=en:hla-b*5801 assay negative | n2=en:galectin-3 abnormal | rel=r_associated | relid=0 | w=41
  4. en:hla-b*5801 assay negative -- r_associated #0: 40 / 0.93 -> en:cancer antigen 15-3 measurement
    n1=en:hla-b*5801 assay negative | n2=en:cancer antigen 15-3 measurement | rel=r_associated | relid=0 | w=40
  5. en:hla-b*5801 assay negative -- r_associated #0: 40 / 0.93 -> en:hla-b*1502 assay negative
    n1=en:hla-b*5801 assay negative | n2=en:hla-b*1502 assay negative | rel=r_associated | relid=0 | w=40
  6. en:hla-b*5801 assay negative -- r_associated #0: 39 / 0.907 -> en:ccr5 receptor positive
    n1=en:hla-b*5801 assay negative | n2=en:ccr5 receptor positive | rel=r_associated | relid=0 | w=39
  7. en:hla-b*5801 assay negative -- r_associated #0: 36 / 0.837 -> en:carcinoembryonic antigen decreased
    n1=en:hla-b*5801 assay negative | n2=en:carcinoembryonic antigen decreased | rel=r_associated | relid=0 | w=36
  8. en:hla-b*5801 assay negative -- r_associated #0: 35 / 0.814 -> en:angiogenesis biomarker
    n1=en:hla-b*5801 assay negative | n2=en:angiogenesis biomarker | rel=r_associated | relid=0 | w=35
  9. en:hla-b*5801 assay negative -- r_associated #0: 35 / 0.814 -> en:cd49d expression increased
    n1=en:hla-b*5801 assay negative | n2=en:cd49d expression increased | rel=r_associated | relid=0 | w=35
  10. en:hla-b*5801 assay negative -- r_associated #0: 35 / 0.814 -> en:hla-b*27 assay
    n1=en:hla-b*5801 assay negative | n2=en:hla-b*27 assay | rel=r_associated | relid=0 | w=35
  11. en:hla-b*5801 assay negative -- r_associated #0: 34 / 0.791 -> en:angiogenesis biomarker increased
    n1=en:hla-b*5801 assay negative | n2=en:angiogenesis biomarker increased | rel=r_associated | relid=0 | w=34
  12. en:hla-b*5801 assay negative -- r_associated #0: 34 / 0.791 -> en:cancer antigen 27-29 measurement
    n1=en:hla-b*5801 assay negative | n2=en:cancer antigen 27-29 measurement | rel=r_associated | relid=0 | w=34
  13. en:hla-b*5801 assay negative -- r_associated #0: 34 / 0.791 -> en:carbohydrate antigen 125 normal
    n1=en:hla-b*5801 assay negative | n2=en:carbohydrate antigen 125 normal | rel=r_associated | relid=0 | w=34
  14. en:hla-b*5801 assay negative -- r_associated #0: 34 / 0.791 -> en:carbohydrate antigen 19-9 increased
    n1=en:hla-b*5801 assay negative | n2=en:carbohydrate antigen 19-9 increased | rel=r_associated | relid=0 | w=34
  15. en:hla-b*5801 assay negative -- r_associated #0: 34 / 0.791 -> en:cd49d expression decreased
    n1=en:hla-b*5801 assay negative | n2=en:cd49d expression decreased | rel=r_associated | relid=0 | w=34
  16. en:hla-b*5801 assay negative -- r_associated #0: 34 / 0.791 -> en:cell marker decreased
    n1=en:hla-b*5801 assay negative | n2=en:cell marker decreased | rel=r_associated | relid=0 | w=34
  17. en:hla-b*5801 assay negative -- r_associated #0: 34 / 0.791 -> en:neuron specific enolase measurement
    n1=en:hla-b*5801 assay negative | n2=en:neuron specific enolase measurement | rel=r_associated | relid=0 | w=34
  18. en:hla-b*5801 assay negative -- r_associated #0: 34 / 0.791 -> en:prostate specific antigen abnormal
    n1=en:hla-b*5801 assay negative | n2=en:prostate specific antigen abnormal | rel=r_associated | relid=0 | w=34
  19. en:hla-b*5801 assay negative -- r_associated #0: 32 / 0.744 -> en:angiogenesis biomarker decreased
    n1=en:hla-b*5801 assay negative | n2=en:angiogenesis biomarker decreased | rel=r_associated | relid=0 | w=32
  20. en:hla-b*5801 assay negative -- r_associated #0: 32 / 0.744 -> en:c-kit receptor assay
    n1=en:hla-b*5801 assay negative | n2=en:c-kit receptor assay | rel=r_associated | relid=0 | w=32
  21. en:hla-b*5801 assay negative -- r_associated #0: 32 / 0.744 -> en:cancer antigen 19-9 measurement
    n1=en:hla-b*5801 assay negative | n2=en:cancer antigen 19-9 measurement | rel=r_associated | relid=0 | w=32
  22. en:hla-b*5801 assay negative -- r_associated #0: 32 / 0.744 -> en:cluster of differentiation antigen detection
    n1=en:hla-b*5801 assay negative | n2=en:cluster of differentiation antigen detection | rel=r_associated | relid=0 | w=32
  23. en:hla-b*5801 assay negative -- r_associated #0: 32 / 0.744 -> en:hla marker study
    n1=en:hla-b*5801 assay negative | n2=en:hla marker study | rel=r_associated | relid=0 | w=32
  24. en:hla-b*5801 assay negative -- r_associated #0: 32 / 0.744 -> en:neurone-specific enolase decreased
    n1=en:hla-b*5801 assay negative | n2=en:neurone-specific enolase decreased | rel=r_associated | relid=0 | w=32
  25. en:hla-b*5801 assay negative -- r_associated #0: 31 / 0.721 -> en:anaplastic lymphoma receptor tyrosine kinase assay
    n1=en:hla-b*5801 assay negative | n2=en:anaplastic lymphoma receptor tyrosine kinase assay | rel=r_associated | relid=0 | w=31
  26. en:hla-b*5801 assay negative -- r_associated #0: 31 / 0.721 -> en:cell marker
    n1=en:hla-b*5801 assay negative | n2=en:cell marker | rel=r_associated | relid=0 | w=31
  27. en:hla-b*5801 assay negative -- r_associated #0: 31 / 0.721 -> en:raised prostate specific antigen
    n1=en:hla-b*5801 assay negative | n2=en:raised prostate specific antigen | rel=r_associated | relid=0 | w=31
  28. en:hla-b*5801 assay negative -- r_associated #0: 31 / 0.721 -> en:tissue polypeptide antigen increased
    n1=en:hla-b*5801 assay negative | n2=en:tissue polypeptide antigen increased | rel=r_associated | relid=0 | w=31
  29. en:hla-b*5801 assay negative -- r_associated #0: 30 / 0.698 -> en:androgen receptor assay
    n1=en:hla-b*5801 assay negative | n2=en:androgen receptor assay | rel=r_associated | relid=0 | w=30
  30. en:hla-b*5801 assay negative -- r_associated #0: 30 / 0.698 -> en:cd20 antigen positive
    n1=en:hla-b*5801 assay negative | n2=en:cd20 antigen positive | rel=r_associated | relid=0 | w=30
  31. en:hla-b*5801 assay negative -- r_associated #0: 30 / 0.698 -> en:cd25 antigen positive
    n1=en:hla-b*5801 assay negative | n2=en:cd25 antigen positive | rel=r_associated | relid=0 | w=30
  32. en:hla-b*5801 assay negative -- r_associated #0: 30 / 0.698 -> en:cell marker increased
    n1=en:hla-b*5801 assay negative | n2=en:cell marker increased | rel=r_associated | relid=0 | w=30
  33. en:hla-b*5801 assay negative -- r_associated #0: 30 / 0.698 -> en:cytokeratin 18 (lab procedure)
    n1=en:hla-b*5801 assay negative | n2=en:cytokeratin 18 (lab procedure) | rel=r_associated | relid=0 | w=30
  34. en:hla-b*5801 assay negative -- r_associated #0: 30 / 0.698 -> en:galectin-3 test
    n1=en:hla-b*5801 assay negative | n2=en:galectin-3 test | rel=r_associated | relid=0 | w=30
  35. en:hla-b*5801 assay negative -- r_associated #0: 30 / 0.698 -> en:hla-b*1502 assay
    n1=en:hla-b*5801 assay negative | n2=en:hla-b*1502 assay | rel=r_associated | relid=0 | w=30
  36. en:hla-b*5801 assay negative -- r_associated #0: 30 / 0.698 -> en:hla-b*5701 assay positive
    n1=en:hla-b*5801 assay negative | n2=en:hla-b*5701 assay positive | rel=r_associated | relid=0 | w=30
  37. en:hla-b*5801 assay negative -- r_associated #0: 30 / 0.698 -> en:human leukocyte antigen a 3101 antigen present
    n1=en:hla-b*5801 assay negative | n2=en:human leukocyte antigen a 3101 antigen present | rel=r_associated | relid=0 | w=30
  38. en:hla-b*5801 assay negative -- r_associated #0: 30 / 0.698 -> en:progesterone receptor assay
    n1=en:hla-b*5801 assay negative | n2=en:progesterone receptor assay | rel=r_associated | relid=0 | w=30
  39. en:hla-b*5801 assay negative -- r_associated #0: 29 / 0.674 -> en:carbohydrate antigen 15-3 increased
    n1=en:hla-b*5801 assay negative | n2=en:carbohydrate antigen 15-3 increased | rel=r_associated | relid=0 | w=29
  40. en:hla-b*5801 assay negative -- r_associated #0: 29 / 0.674 -> en:carbohydrate antigen 549 measurement
    n1=en:hla-b*5801 assay negative | n2=en:carbohydrate antigen 549 measurement | rel=r_associated | relid=0 | w=29
  41. en:hla-b*5801 assay negative -- r_associated #0: 29 / 0.674 -> en:galectin-3 increased
    n1=en:hla-b*5801 assay negative | n2=en:galectin-3 increased | rel=r_associated | relid=0 | w=29
  42. en:hla-b*5801 assay negative -- r_associated #0: 29 / 0.674 -> en:oestrogen receptor assay negative
    n1=en:hla-b*5801 assay negative | n2=en:oestrogen receptor assay negative | rel=r_associated | relid=0 | w=29
  43. en:hla-b*5801 assay negative -- r_associated #0: 29 / 0.674 -> en:progesterone receptor assay negative
    n1=en:hla-b*5801 assay negative | n2=en:progesterone receptor assay negative | rel=r_associated | relid=0 | w=29
  44. en:hla-b*5801 assay negative -- r_associated #0: 29 / 0.674 -> en:tumor marker measurement
    n1=en:hla-b*5801 assay negative | n2=en:tumor marker measurement | rel=r_associated | relid=0 | w=29
  45. en:hla-b*5801 assay negative -- r_associated #0: 29 / 0.674 -> en:tumour marker increased
    n1=en:hla-b*5801 assay negative | n2=en:tumour marker increased | rel=r_associated | relid=0 | w=29
  46. en:hla-b*5801 assay negative -- r_associated #0: 28 / 0.651 -> en:abnormal tumor markers
    n1=en:hla-b*5801 assay negative | n2=en:abnormal tumor markers | rel=r_associated | relid=0 | w=28
  47. en:hla-b*5801 assay negative -- r_associated #0: 28 / 0.651 -> en:cd30 expression
    n1=en:hla-b*5801 assay negative | n2=en:cd30 expression | rel=r_associated | relid=0 | w=28
  48. en:hla-b*5801 assay negative -- r_associated #0: 28 / 0.651 -> en:estrogen receptor assay (era) (procedure)
    n1=en:hla-b*5801 assay negative | n2=en:estrogen receptor assay (era) (procedure) | rel=r_associated | relid=0 | w=28
  49. en:hla-b*5801 assay negative -- r_associated #0: 28 / 0.651 -> en:free prostate-specific antigen positive
    n1=en:hla-b*5801 assay negative | n2=en:free prostate-specific antigen positive | rel=r_associated | relid=0 | w=28
  50. en:hla-b*5801 assay negative -- r_associated #0: 28 / 0.651 -> en:galectin-3 decreased
    n1=en:hla-b*5801 assay negative | n2=en:galectin-3 decreased | rel=r_associated | relid=0 | w=28
  51. en:hla-b*5801 assay negative -- r_associated #0: 28 / 0.651 -> en:hla-b*1502 assay positive
    n1=en:hla-b*5801 assay negative | n2=en:hla-b*1502 assay positive | rel=r_associated | relid=0 | w=28
  52. en:hla-b*5801 assay negative -- r_associated #0: 28 / 0.651 -> en:percent free prostate-specific antigen
    n1=en:hla-b*5801 assay negative | n2=en:percent free prostate-specific antigen | rel=r_associated | relid=0 | w=28
  53. en:hla-b*5801 assay negative -- r_associated #0: 27 / 0.628 -> en:carbohydrate antigen 27.29 increased
    n1=en:hla-b*5801 assay negative | n2=en:carbohydrate antigen 27.29 increased | rel=r_associated | relid=0 | w=27
  54. en:hla-b*5801 assay negative -- r_associated #0: 27 / 0.628 -> en:carbohydrate antigen 549 increased
    n1=en:hla-b*5801 assay negative | n2=en:carbohydrate antigen 549 increased | rel=r_associated | relid=0 | w=27
  55. en:hla-b*5801 assay negative -- r_associated #0: 27 / 0.628 -> en:carcinoembryonic antigen increased
    n1=en:hla-b*5801 assay negative | n2=en:carcinoembryonic antigen increased | rel=r_associated | relid=0 | w=27
  56. en:hla-b*5801 assay negative -- r_associated #0: 27 / 0.628 -> en:fms-like tyrosine kinase 3 positive
    n1=en:hla-b*5801 assay negative | n2=en:fms-like tyrosine kinase 3 positive | rel=r_associated | relid=0 | w=27
  57. en:hla-b*5801 assay negative -- r_associated #0: 27 / 0.628 -> en:free prostate-specific antigen decreased
    n1=en:hla-b*5801 assay negative | n2=en:free prostate-specific antigen decreased | rel=r_associated | relid=0 | w=27
  58. en:hla-b*5801 assay negative -- r_associated #0: 27 / 0.628 -> en:free prostate-specific antigen negative
    n1=en:hla-b*5801 assay negative | n2=en:free prostate-specific antigen negative | rel=r_associated | relid=0 | w=27
  59. en:hla-b*5801 assay negative -- r_associated #0: 27 / 0.628 -> en:hla-b*5701 assay
    n1=en:hla-b*5801 assay negative | n2=en:hla-b*5701 assay | rel=r_associated | relid=0 | w=27
  60. en:hla-b*5801 assay negative -- r_associated #0: 27 / 0.628 -> en:increased cancer antigen 125
    n1=en:hla-b*5801 assay negative | n2=en:increased cancer antigen 125 | rel=r_associated | relid=0 | w=27
  61. en:hla-b*5801 assay negative -- r_associated #0: 27 / 0.628 -> en:prostate specific antigen normal
    n1=en:hla-b*5801 assay negative | n2=en:prostate specific antigen normal | rel=r_associated | relid=0 | w=27
  62. en:hla-b*5801 assay negative -- r_associated #0: 26 / 0.605 -> en:ca-125 measurement
    n1=en:hla-b*5801 assay negative | n2=en:ca-125 measurement | rel=r_associated | relid=0 | w=26
  63. en:hla-b*5801 assay negative -- r_associated #0: 26 / 0.605 -> en:carcinoembryonic antigen measurement
    n1=en:hla-b*5801 assay negative | n2=en:carcinoembryonic antigen measurement | rel=r_associated | relid=0 | w=26
  64. en:hla-b*5801 assay negative -- r_associated #0: 26 / 0.605 -> en:carcinoembryonic antigen normal
    n1=en:hla-b*5801 assay negative | n2=en:carcinoembryonic antigen normal | rel=r_associated | relid=0 | w=26
  65. en:hla-b*5801 assay negative -- r_associated #0: 26 / 0.605 -> en:cell marker analysis
    n1=en:hla-b*5801 assay negative | n2=en:cell marker analysis | rel=r_associated | relid=0 | w=26
  66. en:hla-b*5801 assay negative -- r_associated #0: 26 / 0.605 -> en:free prostate-specific antigen increased
    n1=en:hla-b*5801 assay negative | n2=en:free prostate-specific antigen increased | rel=r_associated | relid=0 | w=26
  67. en:hla-b*5801 assay negative -- r_associated #0: 26 / 0.605 -> en:hla-b*27 positive
    n1=en:hla-b*5801 assay negative | n2=en:hla-b*27 positive | rel=r_associated | relid=0 | w=26
  68. en:hla-b*5801 assay negative -- r_associated #0: 26 / 0.605 -> en:hla-b*5801 assay
    n1=en:hla-b*5801 assay negative | n2=en:hla-b*5801 assay | rel=r_associated | relid=0 | w=26
  69. en:hla-b*5801 assay negative -- r_associated #0: 26 / 0.605 -> en:human epidermal growth factor receptor increased
    n1=en:hla-b*5801 assay negative | n2=en:human epidermal growth factor receptor increased | rel=r_associated | relid=0 | w=26
  70. en:hla-b*5801 assay negative -- r_associated #0: 26 / 0.605 -> en:oestrogen receptor assay positive
    n1=en:hla-b*5801 assay negative | n2=en:oestrogen receptor assay positive | rel=r_associated | relid=0 | w=26
  71. en:hla-b*5801 assay negative -- r_associated #0: 26 / 0.605 -> en:platelet-derived growth factor receptor assay
    n1=en:hla-b*5801 assay negative | n2=en:platelet-derived growth factor receptor assay | rel=r_associated | relid=0 | w=26
  72. en:hla-b*5801 assay negative -- r_associated #0: 25 / 0.581 -> en:cytokeratin 18 increased
    n1=en:hla-b*5801 assay negative | n2=en:cytokeratin 18 increased | rel=r_associated | relid=0 | w=25
  73. en:hla-b*5801 assay negative -- r_associated #0: 24 / 0.558 -> en:galectin-3 normal
    n1=en:hla-b*5801 assay negative | n2=en:galectin-3 normal | rel=r_associated | relid=0 | w=24
  74. en:hla-b*5801 assay negative -- r_associated #0: 22 / 0.512 -> en:human epidermal growth factor receptor negative
    n1=en:hla-b*5801 assay negative | n2=en:human epidermal growth factor receptor negative | rel=r_associated | relid=0 | w=22
  75. en:hla-b*5801 assay negative -- r_associated #0: 22 / 0.512 -> en:immunophenotyping
    n1=en:hla-b*5801 assay negative | n2=en:immunophenotyping | rel=r_associated | relid=0 | w=22
  76. en:hla-b*5801 assay negative -- r_associated #0: 20 / 0.465 -> antigène prostatique spécifique libre négatif
    n1=en:hla-b*5801 assay negative | n2=antigène prostatique spécifique libre négatif | rel=r_associated | relid=0 | w=20
  77. en:hla-b*5801 assay negative -- r_associated #0: 20 / 0.465 -> ca 19-9 augmenté
    n1=en:hla-b*5801 assay negative | n2=ca 19-9 augmenté | rel=r_associated | relid=0 | w=20
  78. en:hla-b*5801 assay negative -- r_associated #0: 20 / 0.465 -> en:tumour marker decreased
    n1=en:hla-b*5801 assay negative | n2=en:tumour marker decreased | rel=r_associated | relid=0 | w=20
≈ 85 relations entrantes

  1. antigène prostatique spécifique libre négatif --- r_associated #0: 68 --> en:hla-b*5801 assay negative
    n1=antigène prostatique spécifique libre négatif | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=68
  2. en:free prostate-specific antigen negative --- r_associated #0: 66 --> en:hla-b*5801 assay negative
    n1=en:free prostate-specific antigen negative | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=66
  3. ca 19-9 augmenté --- r_associated #0: 45 --> en:hla-b*5801 assay negative
    n1=ca 19-9 augmenté | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=45
  4. en:carbohydrate antigen 19-9 increased --- r_associated #0: 39 --> en:hla-b*5801 assay negative
    n1=en:carbohydrate antigen 19-9 increased | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=39
  5. en:galectin-3 decreased --- r_associated #0: 38 --> en:hla-b*5801 assay negative
    n1=en:galectin-3 decreased | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=38
  6. en:free prostate-specific antigen decreased --- r_associated #0: 35 --> en:hla-b*5801 assay negative
    n1=en:free prostate-specific antigen decreased | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=35
  7. en:galectin-3 test --- r_associated #0: 35 --> en:hla-b*5801 assay negative
    n1=en:galectin-3 test | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=35
  8. en:hla marker study --- r_associated #0: 35 --> en:hla-b*5801 assay negative
    n1=en:hla marker study | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=35
  9. en:hla-b*27 assay --- r_associated #0: 35 --> en:hla-b*5801 assay negative
    n1=en:hla-b*27 assay | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=35
  10. en:anaplastic lymphoma receptor tyrosine kinase assay --- r_associated #0: 34 --> en:hla-b*5801 assay negative
    n1=en:anaplastic lymphoma receptor tyrosine kinase assay | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=34
  11. en:carbohydrate antigen 125 normal --- r_associated #0: 34 --> en:hla-b*5801 assay negative
    n1=en:carbohydrate antigen 125 normal | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=34
  12. en:carcinoembryonic antigen measurement --- r_associated #0: 34 --> en:hla-b*5801 assay negative
    n1=en:carcinoembryonic antigen measurement | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=34
  13. en:free prostate-specific antigen increased --- r_associated #0: 34 --> en:hla-b*5801 assay negative
    n1=en:free prostate-specific antigen increased | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=34
  14. en:free prostate-specific antigen positive --- r_associated #0: 34 --> en:hla-b*5801 assay negative
    n1=en:free prostate-specific antigen positive | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=34
  15. en:hla-b*1502 assay negative --- r_associated #0: 34 --> en:hla-b*5801 assay negative
    n1=en:hla-b*1502 assay negative | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=34
  16. en:neurone-specific enolase decreased --- r_associated #0: 34 --> en:hla-b*5801 assay negative
    n1=en:neurone-specific enolase decreased | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=34
  17. en:angiogenesis biomarker --- r_associated #0: 32 --> en:hla-b*5801 assay negative
    n1=en:angiogenesis biomarker | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=32
  18. en:cell marker --- r_associated #0: 32 --> en:hla-b*5801 assay negative
    n1=en:cell marker | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=32
  19. en:galectin-3 abnormal --- r_associated #0: 32 --> en:hla-b*5801 assay negative
    n1=en:galectin-3 abnormal | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=32
  20. en:hla-b*27 positive --- r_associated #0: 32 --> en:hla-b*5801 assay negative
    n1=en:hla-b*27 positive | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=32
  21. en:hla-b*5801 assay --- r_associated #0: 32 --> en:hla-b*5801 assay negative
    n1=en:hla-b*5801 assay | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=32
  22. en:progesterone receptor assay --- r_associated #0: 32 --> en:hla-b*5801 assay negative
    n1=en:progesterone receptor assay | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=32
  23. en:cancer antigen 27-29 measurement --- r_associated #0: 31 --> en:hla-b*5801 assay negative
    n1=en:cancer antigen 27-29 measurement | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=31
  24. en:carcinoembryonic antigen normal --- r_associated #0: 31 --> en:hla-b*5801 assay negative
    n1=en:carcinoembryonic antigen normal | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=31
  25. en:cd49d expression --- r_associated #0: 31 --> en:hla-b*5801 assay negative
    n1=en:cd49d expression | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=31
  26. en:galectin-3 increased --- r_associated #0: 31 --> en:hla-b*5801 assay negative
    n1=en:galectin-3 increased | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=31
  27. en:galectin-3 normal --- r_associated #0: 31 --> en:hla-b*5801 assay negative
    n1=en:galectin-3 normal | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=31
  28. en:increased cancer antigen 125 --- r_associated #0: 31 --> en:hla-b*5801 assay negative
    n1=en:increased cancer antigen 125 | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=31
  29. en:percent free prostate-specific antigen --- r_associated #0: 31 --> en:hla-b*5801 assay negative
    n1=en:percent free prostate-specific antigen | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=31
  30. en:tumor marker measurement --- r_associated #0: 31 --> en:hla-b*5801 assay negative
    n1=en:tumor marker measurement | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=31
  31. en:tumour marker increased --- r_associated #0: 31 --> en:hla-b*5801 assay negative
    n1=en:tumour marker increased | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=31
  32. en:angiogenesis biomarker increased --- r_associated #0: 30 --> en:hla-b*5801 assay negative
    n1=en:angiogenesis biomarker increased | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=30
  33. en:carbohydrate antigen 15-3 increased --- r_associated #0: 30 --> en:hla-b*5801 assay negative
    n1=en:carbohydrate antigen 15-3 increased | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=30
  34. en:carcinoembryonic antigen decreased --- r_associated #0: 30 --> en:hla-b*5801 assay negative
    n1=en:carcinoembryonic antigen decreased | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=30
  35. en:ccr5 receptor positive --- r_associated #0: 30 --> en:hla-b*5801 assay negative
    n1=en:ccr5 receptor positive | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=30
  36. en:cd25 antigen positive --- r_associated #0: 30 --> en:hla-b*5801 assay negative
    n1=en:cd25 antigen positive | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=30
  37. en:cd49d expression decreased --- r_associated #0: 30 --> en:hla-b*5801 assay negative
    n1=en:cd49d expression decreased | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=30
  38. en:cytokeratin 18 increased --- r_associated #0: 30 --> en:hla-b*5801 assay negative
    n1=en:cytokeratin 18 increased | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=30
  39. en:estrogen receptor assay (era) (procedure) --- r_associated #0: 30 --> en:hla-b*5801 assay negative
    n1=en:estrogen receptor assay (era) (procedure) | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=30
  40. en:human epidermal growth factor receptor negative --- r_associated #0: 30 --> en:hla-b*5801 assay negative
    n1=en:human epidermal growth factor receptor negative | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=30
  41. en:c-kit receptor assay --- r_associated #0: 29 --> en:hla-b*5801 assay negative
    n1=en:c-kit receptor assay | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=29
  42. en:cancer antigen 19-9 measurement --- r_associated #0: 29 --> en:hla-b*5801 assay negative
    n1=en:cancer antigen 19-9 measurement | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=29
  43. en:cell marker decreased --- r_associated #0: 29 --> en:hla-b*5801 assay negative
    n1=en:cell marker decreased | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=29
  44. en:hla-b*1502 assay positive --- r_associated #0: 29 --> en:hla-b*5801 assay negative
    n1=en:hla-b*1502 assay positive | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=29
  45. en:hla-b*5701 assay --- r_associated #0: 29 --> en:hla-b*5801 assay negative
    n1=en:hla-b*5701 assay | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=29
  46. en:cell marker increased --- r_associated #0: 28 --> en:hla-b*5801 assay negative
    n1=en:cell marker increased | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=28
  47. en:cytokeratin 18 (lab procedure) --- r_associated #0: 28 --> en:hla-b*5801 assay negative
    n1=en:cytokeratin 18 (lab procedure) | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=28
  48. en:oestrogen receptor assay negative --- r_associated #0: 28 --> en:hla-b*5801 assay negative
    n1=en:oestrogen receptor assay negative | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=28
  49. en:cancer antigen 15-3 measurement --- r_associated #0: 27 --> en:hla-b*5801 assay negative
    n1=en:cancer antigen 15-3 measurement | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=27
  50. en:carbohydrate antigen 27.29 increased --- r_associated #0: 27 --> en:hla-b*5801 assay negative
    n1=en:carbohydrate antigen 27.29 increased | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=27
  51. en:carcinoembryonic antigen increased --- r_associated #0: 27 --> en:hla-b*5801 assay negative
    n1=en:carcinoembryonic antigen increased | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=27
  52. en:cd20 antigen positive --- r_associated #0: 27 --> en:hla-b*5801 assay negative
    n1=en:cd20 antigen positive | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=27
  53. en:cd30 expression --- r_associated #0: 27 --> en:hla-b*5801 assay negative
    n1=en:cd30 expression | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=27
  54. en:cluster of differentiation antigen detection --- r_associated #0: 27 --> en:hla-b*5801 assay negative
    n1=en:cluster of differentiation antigen detection | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=27
  55. en:hla-b*5701 assay positive --- r_associated #0: 27 --> en:hla-b*5801 assay negative
    n1=en:hla-b*5701 assay positive | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=27
  56. en:immunophenotyping --- r_associated #0: 27 --> en:hla-b*5801 assay negative
    n1=en:immunophenotyping | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=27
  57. en:oestrogen receptor assay positive --- r_associated #0: 27 --> en:hla-b*5801 assay negative
    n1=en:oestrogen receptor assay positive | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=27
  58. en:prostate specific antigen normal --- r_associated #0: 27 --> en:hla-b*5801 assay negative
    n1=en:prostate specific antigen normal | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=27
  59. en:tissue polypeptide antigen increased --- r_associated #0: 27 --> en:hla-b*5801 assay negative
    n1=en:tissue polypeptide antigen increased | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=27
  60. en:abnormal tumor markers --- r_associated #0: 26 --> en:hla-b*5801 assay negative
    n1=en:abnormal tumor markers | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=26
  61. en:androgen receptor assay --- r_associated #0: 26 --> en:hla-b*5801 assay negative
    n1=en:androgen receptor assay | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=26
  62. en:angiogenesis biomarker decreased --- r_associated #0: 26 --> en:hla-b*5801 assay negative
    n1=en:angiogenesis biomarker decreased | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=26
  63. en:ca-125 measurement --- r_associated #0: 26 --> en:hla-b*5801 assay negative
    n1=en:ca-125 measurement | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=26
  64. en:carbohydrate antigen 549 increased --- r_associated #0: 26 --> en:hla-b*5801 assay negative
    n1=en:carbohydrate antigen 549 increased | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=26
  65. en:carbohydrate antigen 549 measurement --- r_associated #0: 26 --> en:hla-b*5801 assay negative
    n1=en:carbohydrate antigen 549 measurement | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=26
  66. en:cd49d expression increased --- r_associated #0: 26 --> en:hla-b*5801 assay negative
    n1=en:cd49d expression increased | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=26
  67. en:fms-like tyrosine kinase 3 positive --- r_associated #0: 26 --> en:hla-b*5801 assay negative
    n1=en:fms-like tyrosine kinase 3 positive | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=26
  68. en:hla-b*1502 assay --- r_associated #0: 26 --> en:hla-b*5801 assay negative
    n1=en:hla-b*1502 assay | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=26
  69. en:prostate specific antigen abnormal --- r_associated #0: 26 --> en:hla-b*5801 assay negative
    n1=en:prostate specific antigen abnormal | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=26
  70. en:tumour marker decreased --- r_associated #0: 26 --> en:hla-b*5801 assay negative
    n1=en:tumour marker decreased | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=26
  71. en:human leukocyte antigen a 3101 antigen present --- r_associated #0: 25 --> en:hla-b*5801 assay negative
    n1=en:human leukocyte antigen a 3101 antigen present | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=25
  72. en:raised prostate specific antigen --- r_associated #0: 25 --> en:hla-b*5801 assay negative
    n1=en:raised prostate specific antigen | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=25
  73. en:cell marker analysis --- r_associated #0: 24 --> en:hla-b*5801 assay negative
    n1=en:cell marker analysis | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=24
  74. en:human epidermal growth factor receptor increased --- r_associated #0: 24 --> en:hla-b*5801 assay negative
    n1=en:human epidermal growth factor receptor increased | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=24
  75. en:il-2 receptor assay --- r_associated #0: 24 --> en:hla-b*5801 assay negative
    n1=en:il-2 receptor assay | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=24
  76. en:platelet-derived growth factor receptor assay --- r_associated #0: 24 --> en:hla-b*5801 assay negative
    n1=en:platelet-derived growth factor receptor assay | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=24
  77. en:progesterone receptor assay negative --- r_associated #0: 24 --> en:hla-b*5801 assay negative
    n1=en:progesterone receptor assay negative | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=24
  78. en:neuron specific enolase measurement --- r_associated #0: 21 --> en:hla-b*5801 assay negative
    n1=en:neuron specific enolase measurement | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=21
  79. antigène prostatique spécifique augmenté --- r_associated #0: 15 --> en:hla-b*5801 assay negative
    n1=antigène prostatique spécifique augmenté | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=15
  80. antigène spécifique prostatique augmenté --- r_associated #0: 15 --> en:hla-b*5801 assay negative
    n1=antigène spécifique prostatique augmenté | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=15
  81. asp augmenté --- r_associated #0: 10 --> en:hla-b*5801 assay negative
    n1=asp augmenté | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=10
  82. test de la tyrosine kinase du récepteur du lymphome anaplasique --- r_associated #0: 10 --> en:hla-b*5801 assay negative
    n1=test de la tyrosine kinase du récepteur du lymphome anaplasique | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=10
  83. test du récepteur des androgènes --- r_associated #0: 10 --> en:hla-b*5801 assay negative
    n1=test du récepteur des androgènes | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=10
  84. Mesure de marqueur tumoral --- r_associated #0: 5 --> en:hla-b*5801 assay negative
    n1=Mesure de marqueur tumoral | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=5
  85. antigène spécifique à la prostate augmenté --- r_associated #0: 5 --> en:hla-b*5801 assay negative
    n1=antigène spécifique à la prostate augmenté | n2=en:hla-b*5801 assay negative | rel=r_associated | relid=0 | w=5
Le service Rézo permet d'énumérer les relations existant pour un terme. Ce service est interrogeable par programme.
Projet JeuxDeMots - url: http://www.jeuxdemots.org
contact: mathieu.lafourcade@lirmm.fr